Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma

References

• Abu Lila AS, Ishida T, Kiwada H. (2010). Targeting anticancer drugs to tumor vasculature using cationic liposomes. Pharm Res 27: 1171–83.
   PubMed Web of Science ®Google Scholar
• Allison DC, Carney SC, Ahlmann ER, et al. (2012). A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012:704872.
   PubMedGoogle Scholar
• Bousquet M, Noirot C, Accadbled F, et al. (2016). Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations. Ann Oncol 27:738–44.
   PubMed Web of Science ®Google Scholar
• Cao L, Bu R, Oakley JI, et al. (2003). Estrogen receptor-beta modulates synthesis of bone matrix proteins in human osteoblast-like MG63 cells. J Cell Biochem 89:152–64.
   PubMed Web of Science ®Google Scholar
• Chen B, Le W, Wang Y, et al. (2016). Targeting negative surface charges of cancer cells by multifunctional nanoprobes. Theranostics 6:1887–98.
   PubMed Web of Science ®Google Scholar
• Felt O, Buri P, Gurny R. (1998). Chitosan: a unique polysaccharide for drug delivery. Drug Dev Ind Pharm 24: 979–93.
   PubMed Web of Science ®Google Scholar
• Gelperina S, Kisich K, Iseman MD, Heifets L. (2005). The potential  advantages of  nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 172:1487–90.
   PubMed Web of Science ®Google Scholar
• Jhaveri A, Deshpande P, Torchilin V. (2014). Stimuli-sensitive nanopreparations for combination cancer therapy. J Control Release 190:352–70.
   PubMed Web of Science ®Google Scholar
• Kallio A, Guo T, Lamminen E, et al. (2008). Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells. Mol Cell Endocrinol 289:38–48.
   PubMed Web of Science ®Google Scholar
• Kumar MR, Muzzarelli RA, Muzzarelli C, et al. (2004). Chitosan chemistry and pharmaceutical perspectives. Chem Rev 104:6017–84.
   PubMed Web of Science ®Google Scholar
• Lammers T, Kiessling F, Ashford M, et al. (2016). Cancer nanomedicine: is targeting our target? Nat Rev Mater 1:16069.
   PubMed Web of Science ®Google Scholar
• Li J, Huo M, Wang J, et al. (2012). Redox-sensitive micelles self- assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials 33: 2310–20.
   PubMed Web of Science ®Google Scholar
• Lodhi G, Kim YS, Hwang JW, et al. (2014). Chitooligosaccharide and its derivatives:preparation and biological application. BioMed Research International 2014:654913.
   PubMed Web of Science ®Google Scholar
• Lu BY, Chang JY. (2010). Rapid and irreversible reduction of protein disulfide bonds. Anal Biochem 405:67–72.
   PubMed Web of Science ®Google Scholar
• Luo Q, Zhao J, Zhang X, Pan W. (2011). Nanostructured lipid carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 403:185–91.
   PubMed Web of Science ®Google Scholar
• Maeda H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189–207.
   PubMedGoogle Scholar
• Mirabello L, Troisi RJ, Savage SA. (2009). International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 125: 229–34.
   PubMed Web of Science ®Google Scholar
• Mitragotri S, Lammers T, Bae YH, Schwendeman S, De Smedt S, Leroux JC, et al. (2017). Drug delivery research for the future: expanding the nano horizons and beyond. J Control Release 246:183–4.
   PubMed Web of Science ®Google Scholar
• Okuyama K, Noguchi K, Kanenan M, et al. (2000). Strcutural diversity of chitosan and its complexes. Carbohydr Polym 41:237–47.
   Web of Science ®Google Scholar
• Paliwal SR, Paliwal R, Pal HC, et al. (2012). Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy. Mol Pharmaceutics 9:176–86.
   PubMed Web of Science ®Google Scholar
• Qin C, Gao J, Wang L, et al. (2006). Safety evaluation of short-term exposure to chitooligomers from enzymic preparation. Food Chem Toxicol 44:855–61.
   PubMed Web of Science ®Google Scholar
• Rajan R, Sabnani MK, Mavinkurve V, et al. (2017). Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate. J Control Release 271:139–48.
   PubMed Web of Science ®Google Scholar
• Schafer FQ, Buettner GR. (2001). Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30:1191–212.
   PubMed Web of Science ®Google Scholar
• Sultana S, Khan MR, Kumar M, et al. (2013). Nanoparticles-mediated drug delivery approaches for cancer targeting: a review. J Drug Target 21:107–25.
   PubMed Web of Science ®Google Scholar
• Svoboda M, Hamilton G, Thalhammer T. (2010). Steroid hormone metabolizing enzymes in benign and malignant human bone tumors. Expert Opin Drug Metab Toxicol 6:427–37.
   PubMed Web of Science ®Google Scholar
• Swiatkiewicz S, Swiatkiewicz M, Arczewska-Wlosek A, Jozefiak D. (2015). Chitosan and its oligosaccharide derivatives (chito-oligosaccharides) as feed supplements in poultry and swine nutrition. J Anim Physiol Anim Nutr 99:1–12.
   PubMed Web of Science ®Google Scholar
• Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. (2015). Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 200:138–57.
   PubMed Web of Science ®Google Scholar
• Wojtkowiak JW, Verduzco D, Schrammm KJ, Gillies RJ. (2011). Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm 8:2032–8.
   PubMed Web of Science ®Google Scholar
• Xu H, Paxton JW, Li Y, et al. (2014). Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells. Pharm Res 31: 2583–92.
   PubMed Web of Science ®Google Scholar
• Yan L, Crayton SH, Thawani JP, et al. (2015). A pH-responsive drug-delivery platform based on glycol chitosan-coated liposomes. Small 11:4870–4.
   PubMed Web of Science ®Google Scholar
• Yin X, Chi Y, Guo C, et al. (2017). Chitooligosaccharides modified reduction-sensitive liposomes: enhanced cytoplasmic drug delivery and osteosarcomas-tumor inhibition in animal models. Pharm Res 34:2172–84.
   PubMed Web of Science ®Google Scholar
• Yoon HJ, Moon ME, Park HS, et al. (2007). Chitosan oligosaccharide (COS) inhibits LPS-induced inflammatory effects in RAW 264.7 macrophage cells. Biochem Biophys Res Commun 358:954–9.
   PubMed Web of Science ®Google Scholar
• Zheng L, Zhu J. (2003). Study on antimicrobial activity of chitosan with different molecular weights. Carbohydr Polym 54:527–30.
   Web of Science ®Google Scholar